Skip to main content

Table 3 Pap class distribution of included patients of which test results of all 3 assays are available (n = 11,333).

From: HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows

Pap class Bethesda classification Included samples (N) Pap class distribution of tested cohort (DuSC) Pap class distribution of Dutch screening populationa HC2 hrHPV prevalence
%(N)
cobas hrHPV prevalence
%(N)
Aptima hrHPV prevalence
%(N)
Overall hrHPV prevalence
0 - 191 1.7% 1.7% 6.8% (13) 5.2% (10) 4.2% (8) 5.4 ± 1.3%
1 Normal 10,639 93.9% 93.6% 5.8% (620) 5.7% (609) 5.1% (545) 5.5 ± 0.4%
2 ASC-US 314 2.8% 3.0% 47.8% (150) 41.1% (129) 39.5% (124) 42.8 ± 4.4%
3a1 LSIL 71 0.6% 0.7% 91.5% (65) 85.9% (61) 84.5% (60) 87.3 ± 3.7%
3a2 HSIL (moderate) 50 0.4% 0.4% 94.0% (47) 94.0% (47) 94.0% (47) 94.0 ± 0.0%
3b HSIL (severe) 62 0.5% 0.6% 95.2% (59) 93.5% (58) 96.8% (60) 95.2% ± 1.7%
4 CIS/AIS 6 0.01% 0.0% 83.3% (5) 83.3% (5) 83.3% (5) 83.3 ± 0.0%
  Total (N) 11,333    959 919 849  
  1. Number of included samples per Pap class and Pap class distribution of study cohort vs Pap class distribution of the Dutch screening program; and hrHPV prevalences per assay and overall mean
  2. Pap 0 = sample inadequate for cytology
  3. aBased on the Dutch national pathology registry (PALGA database)
  4. ASC-US Atypical Squamous Cells of Undetermined Significance, LSIL Low-grade Squamous Intraepithelial Lesion, HSIL High-grade Squamous Intraepithelial Lesion, CIS Carcinoma in situ, AIS Adenocarcinoma in situ